7 recruiting, 4 not yet recruiting, 3 active not recruiting, 1 completed. 16 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Recruiting 7, Not yet recruiting 4, Active not recruiting 3, Completed 1, Unknown 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Radical Surgery: new trials by email Literature Review of Radical Surgery trials Research Report on Radical Surgery
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma Retlirafusp Alfa, Oxaliplatin, Capecitabine - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tang-Du Hospital | 21 | 2026-08-30 | 2026-07-17 |
| Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer Nivolumab, Ipilimumab (1mg/kg), PULSAR - Colorectal Cancer (MSI-H) | Phase 2 | Not yet recruiting | Fudan University | 114 | 2026-02-01 | 2026-02-11 |
| Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC Camrelizumab, Paclitaxel, carboplatin - Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms | Phase 2 | Not yet recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 50 | 2026-02-01 | 2026-02-10 |
| A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma Radical surgery, TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706) - Hepatocellular Carcinoma, Immunotherapy | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 48 | 2025-08-11 | 2025-08-20 |
| Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma Paclitaxel Polymersomes Combined with Carboplatin and Adebelimab, Radical Surgery - Resectable Mucosal Melanoma | Phase 2 | Recruiting | Sun Yat-sen University | 32 | 2025-03-20 | 2026-01-13 |
| Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC Neoadjuvant Chemotherapy, Immunotherapy, Radical surgery - Cervical Cancers | Phase 2 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 35 | 2025-03-15 | 2025-04-01 |
| Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, Radical surgery - Gastric Cancer, Colon Cancer | Phase 2 | Recruiting | Peking University | 34 | 2024-09-13 | 2026-05-15 |
| Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Camrelizumab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-09-12 | 2025-03-20 |
| Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery - Esophageal Cancer, Immunotherapy | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2024-05-01 | 2025-05-30 |
| Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 / Phase 3 | Recruiting | Tongji Hospital | 440 | 2024-04-22 | 2024-10-30 |
| Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma three cycles (toripalimab + cetuximab + platinum), Radical surgery, Radiotherapy or chemoradiotherapy - Locally Advanced Hypopharyngeal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 32 | 2024-01-18 | 2024-04-30 |
| De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer Paclitaxel, trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Active not recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 186 | 2023-09-01 | 2026-02-27 |
| A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract Enfortumab Vedotin, Radical surgery - Urothelial Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 9 | 2023-06-02 | 2026-08-06 |
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma Camrelizumab, Apatinib Mesylate, Radical surgery - Hepatocellular Carcinoma, Immunotherapy | Phase 2 / Phase 3 | Active not recruiting | Shanghai Zhongshan Hospital | 294 | 2021-03-25 | 2025-05-11 |
| Total/Subtotal Colectomy in Ovarian Cancer Total or Subtotal Colectomy, Other Bowel Resection - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | Shanghai Gynecologic Oncology Group | 80 | 2015-07-01 | 2016-07-26 |
| Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes gemcitabine, cisplatin, radical surgery - Non-Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 13 | 2003-09-01 | 2007-06-25 |
Uterine Cervical Neoplasms (3) · Carcinoma, Hepatocellular (2) · Stomach Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Laryngeal Neoplasms (1) · Mouth Neoplasms (1) · Ovarian Neoplasms (1)
National Medical Research Radiological Centre of the Ministry of Health of Russia (2) · Tongji Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Eli Lilly and Company (1) · Eye & ENT Hospital of Fudan University (1) · Fudan University (1) · Memorial Sloan Kettering Cancer Center (1) · Obstetrics & Gynecology Hospital of Fudan University (1) · Peking University (1) · Shanghai Gynecologic Oncology Group (1) · Shanghai Zhongshan Hospital (1) · Sun Yat-sen University (1) · Tang-Du Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (11) · Russia (2) · Poland (1) · United States (1)
Ding Ma (2) · Jian Zhou, Doctor (1) · Keqin Hua, Doctor (1) · Larisa Bolotina, MD, PhD (1) · Larisa V. Bolotina, MD, PhD (1) · Lei Tao (1) · Lin Shen (1) · Rongyu Zang, MD,PhD (1) · Scot Niglio, MD, MS (1) · Xin Wang (1) · Xuehao Wang (1) · Yongxiang Xia (1)